Qingling Hua1, Yanzhe Zhu2, Hu Liu2, Xiaobing Ye3. 1. Department of Oncology, Yijishan Hospital of Wannan Medical College, No. 2 West Zheshan Road, Wuhu, 241001, China. 2. Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China. 3. Department of Oncology, Yijishan Hospital of Wannan Medical College, No. 2 West Zheshan Road, Wuhu, 241001, China. yexiaobing2015@163.com.
Abstract
BACKGROUND: Biochemical recurrence (BCR), or an elevation in prostate-specific antigen in men after treatment for localized prostate cancer, is an early indication of clinical progression, distant metastases, and mortality. Correlations have also recently been established between diabetes and the incidence and mortality of prostate cancer. However, it remains unknown whether diabetes may predict BCR. METHODS: We performed a meta-analysis of published articles to investigate the prognostic value of diabetes for BCR in prostate cancer. Eight studies and 11,923 patients were included in our meta-analysis. The relative risk (RR) and its 95 % confidence interval (CI) were calculated. RESULTS: We found no apparent association between diabetes and BCR (adjusted RR 1.04; 95 % CI 0.87-1.22). CONCLUSIONS: The evidence of this meta-analysis indicates that diabetes is not a predictor of risk of BCR in patients with prostate cancer.
BACKGROUND: Biochemical recurrence (BCR), or an elevation in prostate-specific antigen in men after treatment for localized prostate cancer, is an early indication of clinical progression, distant metastases, and mortality. Correlations have also recently been established between diabetes and the incidence and mortality of prostate cancer. However, it remains unknown whether diabetes may predict BCR. METHODS: We performed a meta-analysis of published articles to investigate the prognostic value of diabetes for BCR in prostate cancer. Eight studies and 11,923 patients were included in our meta-analysis. The relative risk (RR) and its 95 % confidence interval (CI) were calculated. RESULTS: We found no apparent association between diabetes and BCR (adjusted RR 1.04; 95 % CI 0.87-1.22). CONCLUSIONS: The evidence of this meta-analysis indicates that diabetes is not a predictor of risk of BCR in patients with prostate cancer.
Entities:
Keywords:
Biochemical recurrence; Diabetes; Meta-analysis; Prostate cancer
Authors: J Varlotto; L N Medford-Davis; A Recht; J Flickinger; E Schaefer; J Shelkey; M Lazar; D Campbell; M Nikolov; M M Decamp Journal: Lung Cancer Date: 2011-08-23 Impact factor: 5.705
Authors: Marjolein M J Zanders; Dorry Boll; Liza N van Steenbergen; Lonneke V van de Poll-Franse; Harm R Haak Journal: Maturitas Date: 2012-11-12 Impact factor: 4.342
Authors: Al V Taira; Gregory S Merrick; Robert W Galbreath; Mallory Morris; Wayne M Butler; Edward Adamovich Journal: J Contemp Brachytherapy Date: 2014-10-06